Venezuela: golpe militar y democratización. Apuntes para el debate.

Cuando pensamos en los efectos (autocratizantes o democratizadores) de los golpes, la clave radica en la naturaleza del régimen preexistente. Si este fue mínimamente democrático -como en México en 1911, España en 1936, Perú y Venezuela en 1948, Guatemala en 1954, República Dominica en 1963, Brasil en 1964, Argentina en 1966, Chile en 1973, Haití en 1991 y Honduras en 2009 - un golpe militar siempre y necesariamente será antidemocrático. Pero si el régimen anterior es plenamente autoritario -como en Venezuela en 1945 y 1957-58, Portugal en 1974, Ghana en 1979, Filipinas en 1986, Paraguay en 1989, Egipto en 2011 o Zimbabwe en 2017 - el golpe, al tumbar al régimen, crea la posibilidad de una democratización.

Venezuela: golpe militar y democratización. Apuntes para el debate.

Cuando pensamos en los efectos (autocratizantes o democratizadores) de los golpes, la clave radica en la naturaleza del régimen preexistente. Si este fue mínimamente democrático -como en México en 1911, España en 1936, Perú y Venezuela en 1948, Guatemala en 1954, República Dominica en 1963, Brasil en 1964, Argentina en 1966, Chile en 1973, Haití en 1991 y Honduras en 2009 - un golpe militar siempre y necesariamente será antidemocrático. Pero si el régimen anterior es plenamente autoritario -como en Venezuela en 1945 y 1957-58, Portugal en 1974, Ghana en 1979, Filipinas en 1986, Paraguay en 1989, Egipto en 2011 o Zimbabwe en 2017 - el golpe, al tumbar al régimen, crea la posibilidad de una democratización.

Introduction : media and illiberal democracy in Central and Eastern Europe

This introductory overview opens the series of articles included in the issue entitled Media and Illiberal Democracy in Central and Eastern Europe, and sets the scene for the debate on the relationship between illiberal trends in politics and media landscapes in the region. Drawing on existing scholarship, it traces the roots and the evolution of illiberalism, focusing the discussion within the confines of particularities of media landscapes. Through the introduction of articles addressing manifestations of illiberalism in media landscapes, it argues that “illiberal turn” in Central and Eastern Europe is part of a global political shift, rather than a regional one

Investigation of G72 (DAOA) expression in the human brain

<p>Abstract</p> <p>Background</p> <p>Polymorphisms at the G72/G30 locus on chromosome 13q have been associated with schizophrenia or bipolar disorder in more than ten independent studies. Even though the genetic findings are very robust, the physiological role of the predicted G72 protein has thus far not been resolved. Initial reports suggested G72 as an activator of D-amino acid oxidase (DAO), supporting the glutamate dysfunction hypothesis of schizophrenia. However, these findings have subsequently not been reproduced and reports of endogenous human G72 mRNA and protein expression are extremely limited. In order to better understand the function of this putative schizophrenia susceptibility gene, we attempted to demonstrate G72 mRNA and protein expression in relevant human brain regions.</p> <p>Methods</p> <p>The expression of G72 mRNA was studied by northern blotting and semi-quantitative SYBR-Green and Taqman RT-PCR. Protein expression in human tissue lysates was investigated by western blotting using two custom-made specific anti-G72 peptide antibodies. An in-depth <it>in silico </it>analysis of the G72/G30 locus was performed in order to try and identify motifs or regulatory elements that provide insight to G72 mRNA expression and transcript stability.</p> <p>Results</p> <p>Despite using highly sensitive techniques, we failed to identify significant levels of G72 mRNA in a variety of human tissues (e.g. adult brain, amygdala, caudate nucleus, fetal brain, spinal cord and testis) human cell lines or schizophrenia/control post mortem BA10 samples. Furthermore, using western blotting in combination with sensitive detection methods, we were also unable to detect G72 protein in a number of human brain regions (including cerebellum and amygdala), spinal cord or testis. A detailed <it>in silico </it>analysis provides several lines of evidence that support the apparent low or absent expression of G72.</p> <p>Conclusion</p> <p>Our results suggest that native G72 protein is not normally present in the tissues that we analysed in this study. We also conclude that the lack of demonstrable G72 expression in relevant brain regions does not support a role for G72 in modulation of DAO activity and the pathology of schizophrenia via a DAO-mediated mechanism. <it>In silico </it>analysis suggests that G72 is not robustly expressed and that the transcript is potentially labile. Further studies are required to understand the significance of the G72/30 locus to schizophrenia.</p

A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens:a phase I trial in UK patients with EBV-positive cancer

Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses. Experimental Design: Sixteen patients in the United Kingdom (UK) with EBV-positive nasopharyngeal carcinoma (NPC) received three intradermal vaccinations of MVA-EL at 3-weekly intervals at dose levels between 5 × 107 and 5 × 108 plaque-forming units (pfu). Blood samples were taken at screening, after each vaccine cycle, and during the post-vaccination period. T-cell responses were measured using IFNγ ELISpot assays with overlapping EBNA1/LMP2 peptide mixes or HLA-matched epitope peptides. Polychromatic flow cytometry was used to characterize functionally responsive T-cell populations. Results: Vaccination was generally well tolerated. Immunity increased after vaccination to at least one antigen in 8 of 14 patients (7/14, EBNA1; 6/14, LMP2), including recognition of epitopes that vary between EBV strains associated with different ethnic groups. Immunophenotypic analysis revealed that vaccination induced differentiation and functional diversification of responsive T-cell populations specific for EBNA1 and LMP2 within the CD4 and CD8 compartments, respectively. Conclusions: MVA-EL is safe and immunogenic across diverse ethnicities and thus suitable for use in trials against different EBV-positive cancers globally as well as in South-East Asia where NPC is most common. The highest dose (5 × 108 pfu) is recommended for investigation in current phase IB and II trials. Clin Cancer Res; 20(19); 5009–22. ©2014 AACR